Our Partners
AAIC aims to invest in fast growing companies within the Healthcare sector in Africa. AAIC focuses on providing growth capital as well as long term value to assist companies in improving their performance and expansion. Additionally, AAIC works to synergize Japan’s strength with developing country growth, combining people, funds, knowledge and information. Through this investment philosophy, AAIC aims to realize a mutually beneficial relationship for Japan and its portfolio companies in developing countries, providing the necessary support to ensure sustainability of itsportfolio companies.
www.aaicinvestment.com
DFC is the development finance institution of the United States federal government, primarily responsible for providing and facilitating the financing of private development projects in lower- and middle-income countries. The independent agency was formed in 2019 by merging the Overseas Private Investment Corporation (OPIC) with the Development Credit Authority (DCA) of the United States Agency for International Development (USAID), as well as with several smaller offices and funds.
Africa50 was established to help bridge Africa’s infrastructure funding gap by facilitating project development, mobilizing public and private sector finance, and investing in infrastructure on the continent. Africa50 focuses on medium- to large-scale projects that have development impact and offer an appropriate risk-adjusted return to investors. Bringing project development and financing together in one platform, Africa50 seeks to provide support at every stage of the project cycle.
As part of our supply chain, we work with leading global manufacturers.
Machines and Equipment:
We have agreements with some of the largest manufacturers, bringing top notch machines, reverse osmosis systems, and other equipment.
Consumable Kits:
We work closely (including some exclusive agreements) with large global manufacturers on high quality medical supplies.
Pharmaceuticals:
We source pharmaceuticals from leading companies that meet our rigorous quality-control standards and medication protocols.
Our investors and suppliers provide a distinct competitive advantage, as we can deploy capital quickly to build new centers and leverage economies of scale in our supply chain, ensuring efficient and high quality operations.
